BRIEF—ICER to assess treatments for obesity management

The USA’s Institute for Clinical and Economic Review (ICER) announced that it will assess the comparative clinical effectiveness and value of four weight management products.

The drugs in questions are: subcutaneous Wegovy (semaglutide) from Novo Nordisk; Qsymia (phentermine/topiramate) from Vivus Pharmaceuticals); Saxenda (liraglutide), also from Novo Nordisk); and Contrave (altrexone/bupropion) from Currax Pharma, for the treatment of obesity.

The assessment will be publicly discussed during a meeting of the New England Comparative Effectiveness Public Advisory Council ( New England CEPAC) in September 2022, where the independent evidence review panel will deliberate and vote on evidence presented in the ICER’s report.